The molecular basis for the clinical presentation of broad-range drug resistance in childhood ALL is poorly understood. In this study, high level cross-resistance to the glucocorticoid dexamethasone was encountered in a childhood ALL cell line selected for resistance to methotrexate (CEM MTX-R3). Compared with wild-type (WT) CEM cells, MTX-R3 cells had significantly fewer glucocorticoid binding sites, as well as reduced glucocorticoid receptor protein and mRNA levels. DNA sequencing and restriction fragment-length polymorphism (RFLP) analysis showed that WT cells expressed both a wild-type and a mutant (GR753F) glucocorticoid receptor allele, while MTX-R3 cells expressed only the GR753F allele. Therefore, the crossresistance of MTX-R3 cells to dexamethasone appeared due to loss of expression of the wild-type glucocorticoid receptor allele. In an effort to gain insight into the underlying basis for the development of cross-resistance to methotrexate and glucocorticoids, glucocorticoid receptor nuclear translocation experiments were carried out. Exposure of WT cells to either dexamethasone or the cytotoxic agents cytarabine and methotrexate caused translocation of the glucocorticoid receptor from the cytoplasm into the nucleus. These data indicate that exposure of childhood ALL cells to cytotoxic agents may result in ligand-independent glucocorticoid receptor activation which, in the context of the outgrowth of drug-resistant cells, could lead to the co-selection of glucocorticoid resistance. Leukemia (2001) 15, 929-935.
Introduction
Acute lymphoblastic leukemia (ALL) is the single most common childhood malignancy. Currently, with the use of combination chemotherapy, over 95% of children with ALL undergo a complete clinical remission. However, while over two-thirds of children achieve long-term survival, approximately onethird will relapse. 1 Frequently, the leukemic cells from relapsed patients exhibit broad-range drug resistance, 2 and the molecular basis for this resistance is poorly understood.
Glucocorticoids are routinely used in combination with other cytotoxic drugs for the treatment of ALL because of their lympholytic effects, mediated through a specific cytoplasmic glucocorticoid receptor, leading to rapid reduction of tumor burden. 3 In a study of 271 murine lymphoid cell lines the glucocorticoid receptor was shown to be the primary target for development of glucocorticoid resistance. 4 Resistance to glucocorticoids is significantly increased in childhood ALL patients at relapse compared to diagnosis. 2 The human cell line CCRF-CEM 5 has been used in a number of studies of glucocorticoid resistance in human lymphoblasts. All glucocorticoid-sensitive CEM sub-clones examined have been shown to express one functional glucocorticoid receptor allele and one allele with a point mutation (transversion from A to T) in codon 753, resulting in the substitution of phenylalanine for leucine (GR753F). [6] [7] [8] [9] [10] The protein encoded by the GR753F allele displays an activation labile phenotype. 6, 11 Almost all glucocorticoid-resistant cell lines derived from CEM cells carry mutations or deletions in the wild-type allele. 6, 8, 9 To date, glucocorticoid resistance has primarily been studied in cells selected for dexamethasone resistance.
Studies of cell lines selected for resistance to a single agent which also display resistance to other, structurally unrelated drugs, are potentially informative of mechanisms of multidrug resistance that may be encountered in the clinical management of malignancies. We have previously described a drugresistant CEM subline derived by sequentially exposing the parental cell line to increasing concentrations of methotrexate. 12 This model system enables the study of patterns of methotrexate resistance at extreme, but clinically relevant, drug concentrations. 13 The basis of the methotrexate resistance in the resulting MTX-R3 subline appears to be amplification of the gene encoding the cellular drug target, dihydrofolate reductase, 14, 15 as well as defective drug uptake resulting from a point mutation in the gene encoding the reduced folate carrier. 16 MTX-R3 cells also have increased expression of the MDR1 gene 16 and are cross-resistant to P-glycoprotein substrates such as vincristine, vinblastine and daunorubicin. 12 In this study, we demonstrate that the MTX-R3 cell line exhibits profound resistance to glucocorticoids, with the absence of a functional glucocorticoid receptor providing the most likely explanation for this resistance. Our data provide the first experimental evidence that selection for methotrexate resistance can lead to high-level glucocorticoid resistance. Furthermore, our demonstration that methotrexate induces nuclear translocation of the glucocorticoid receptor in wildtype (WT) CEM cells provides a conceptual basis for the development of cross-resistance between glucocorticoids and cytotoxic drugs in childhood ALL.
Materials and methods

Cell culture
The T-ALL cell line, WT CEM and its methotrexate-resistant derivative MTX-R3 12 were maintained as static suspension cultures at 37°C in RPMI1640 medium buffered with 20 mm Hepes (pH 7.4), and supplemented with penicillin (100 U/ml), streptomycin (100 g/ml), l-glutamine (2 mm) and 10% (v/v) fetal bovine serum (complete medium, CM). Cells were subcultured every 3-4 days and initially seeded at a density of 10 5 cells/ml.
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Cytotoxicity assays
Cells were seeded into 96-well tissue culture plates at a density of 5 × 10 3 cells/100 l CM. The following day 100 l of CM containing various concentrations of methotrexate, cytarabine or dexamethasone were added. Plates were incubated at 37°C in a humidified environment for 72 h, following which mitochondrial metabolic activity was determined by Alamar Blue assay (Serotec, Raleigh, NC, USA), and expressed as a percent of solvent-treated controls. A dose response curve was generated and the concentration of drug resulting in 50% growth inhibition determined.
Glucocorticoid receptor binding assays
The glucocorticoid receptor quantity and affinity were estimated using whole cell and cytoplasmic ligand binding assays. For the whole cell binding assay, either 10 l of Following a 1 h incubation at 37°C with occasional agitation, cells were harvested by centrifugation at 1200 g for 1 min. Cells were then washed four times with warm Hanks balanced salt solution (HBSS) and resuspended in HBSS. By assaying a fraction of this suspension for radioactivity and determining the cell concentration, the number of receptors per cell and the receptor affinity were calculated by the method of Scatchard 17 as described by Harmon and Thompson. 18 Cytoplasmic ligand binding assays were performed essentially as described by Harmon and colleagues. 19 Cells in exponential growth were harvested by centrifugation at 350 g for 5 min and washed twice in HBSS. The cell pellet was placed on dry ice for 20 min, then thawed on wet ice before being resuspended in buffer A (10 mm Hepes (pH 8.0), 1 mm EDTA, 10% glycerol) at a density of 2.5 × 10 8 cells/ml. Lysis of the plasma membrane was confirmed by trypan blue staining. The cell lysate was centrifuged at 10 000 g for 15 min to pellet the nuclei. The protein content of the supernatant was determined using the Bradford method. 20 Aliquots of the cytoplasmic extract (250 g protein in 200 l buffer A) were incubated at 4°C for 3 h with either 2 l 3 H-dexamethasone (0.1 m-10 m) plus 2 l 100% ethanol or 2 l 3 H-dexamethasone (0.1 m-10 m) plus 2 l 1 mm unlabelled dexamethasone in 100% ethanol. Unbound steroid was removed by absorption to 10 mg dextran-coated charcoal (pre-washed in buffer A) and centrifugation at 2200 g for 10 min at 4°C. Fifty l aliquots of the supernatant were assayed for radioactivity by liquid scintillation counting and results were analyzed by the method of Scatchard.
17
Nuclear translocation of cytosolic glucocorticoid receptor
Nuclear translocation of cytosolic glucocorticoid receptor was assessed by immunoblot analysis of cytoplasmic and nuclear extracts. 21 WT cells were exposed to dexamethasone (1 m), cytarabine (ara-C, 100 nm) or methotrexate (1 m) for up to 24 h, harvested and washed with ice-cold PBS. At the time of harvest cell viability was estimated as the proportion of cells that excluded 0.2% trypan blue. Cell pellets were resuspended by gentle pipeting in 450 l of hypotonic lysis buffer (30 mm Tris.Cl, pH 7.5, 1.5 mm MgCl 2 , 10 mm KCl, 20% (v/v) glycerol). Following the addition of 50 l of a solution of 10% (v/v) Triton X-100 and 5% (w/v) sodium deoxycholate, cells were lysed by gentle pipeting, then incubated on ice for 2 min. Nuclei were pelleted by centrifugation at 12 000 g for 1.5 min, and the supernatant (cytoplasm) stored for subsequent analysis. Nuclei were resuspended in 500 l of nuclear extraction buffer (30 mm Tris.Cl, pH 7.5, 1.5 mm MgCl 2 , 500 mm NaCl) and the extraction mixture incubated on ice for 10 min. Following a final centrifugation (12 000 g for 1.5 min) the nuclear extract was removed for subsequent immunoblot analysis.
Immunoblotting
Immunoblot analyses were carried out using standard methods. 22 Briefly, cells were lysed in RIPA buffer (50 mm Tris.Cl, pH 7.5, 150 mm NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) and the protein content determined using the bicinchoninic acid protein assay kit (Pierce, Rockford, IL, USA). Equivalent amounts of protein from whole cell lysates or equal volumes of nuclear extracts and cytoplasmic fractions were separated by SDS-polyacrylamide gel electrophoresis and transferred to polyvinyl difluoride membrane. The membrane was probed with either antihuman glucocorticoid receptor antibody (GR E-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-human actin antibody (Sigma, St Louis, MO, USA). In both cases, the secondary antibody used was a horseradish peroxidase conjugate of donkey anti-rabbit Ig (Amersham Pharmacia Biotech UK, Little Chalfont, UK). Chemiluminescence signals were generated by the addition of SuperSignal Ultra Chemiluminescence Substrate (Pierce) and detected both on radiographic film and quantified by phosphoimage analysis, as we have previously described. 23 
Northern blot analysis of glucocorticoid receptor mRNA
Following cytoplasmic RNA extraction using TRIZOL (LifeTechnologies, Gaithersburg, MD, USA), aliquots of 20 g were electrophoretically separated under denaturing conditions in a 1% agarose gel containing 2% formaldehyde. RNA was capillary transferred overnight with 10 × SSC to GeneScreen Plus membrane (NEN, Boston, MA, USA) using standard procedures. 24 Following transfer, the RNA was immobilized by baking at 70°C for 2 h. DNA probes corresponding to the glucocorticoid receptor or glyceraldehyde 3Ј-phosphate dehydrogenase (GAPDH) control (Table 1) were prepared by reverse transcription-polymerase chain reaction (RT-PCR) amplification, and radiolabeled with ␣-32 P-dCTP (NEN) using the Megaprime DNA Random Labeling System (Amersham). Prehybridization, hybridization and posthybridization washes of the membrane were carried out using standard procedures. 24 Radioactivity was visualized on radiographic film and quantified by phosphoimage analysis, as described above.
RT-PCR, DNA sequencing and RFLP analysis
Two g aliquots of RNA were reverse transcribed using random hexanucleotide primers (Amersham) and Moloney murine leukemia virus reverse transcriptase (Life Technologies). Reactions were incubated at 37°C for 1 h and diluted five-fold in sterile de-ionized water prior to storage at −20°C. Parallel reactions were performed in the absence of reverse transcriptase. Oligonucleotide primer pairs were designed for RT-PCR amplification of glucocorticoid receptor or GAPDH using the MacVector 4.1 Sequence Analysis Software and are summarized in Table 1 . Primer pairs for amplification of the glucocorticoid receptor were selected on the basis that their respective PCR products crossed an exon-intron boundary, and their inability to amplify genomic DNA was verified. Aliquots of cDNA equivalent to 40 ng of the RNA used in the RT reaction were amplified for 35 cycles in a final volume of 25 l with 1 unit of AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, USA). Following an initial denaturation/ hotstart step of 10 min at 94°C, cycles consisted of 0.75 min at 94°C, 0.75 min at 50-55°C (dependent on primer pairs), and 1.5 min at 72°C. A final extension at 72°C for 5 min was performed prior to cooling at 4°C. Water amplification and RT controls were included. Sequencing of PCR products was performed using dye-terminator chemistry.
For RFLP analysis, RT-PCR products were digested with AluI. Reaction products were separated by polyacrylamide gel electrophoresis and stained with ethidium bromide prior to transillumination and digital capture.
Results and discussion
Cross-resistance of MTX-R3 cells to glucocorticoids
Cytotoxicity assays carried out to determine the sensitivity of WT and MTX-R3 cells to methotrexate and dexamethasone confirmed that the MTX-R3 cell line was highly resistant to methotrexate, with an ID 50 of 960 m compared to 10 nm for WT cells, a difference of nearly five orders of magnitude (Figure 1a) . MTX-R3 cells were also highly resistant to
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Figure 1
Cytotoxicity of methotrexate (a) and dexamethasone (b) towards WT (closed circles) and MTX-R3 (open circles) cells. Cells were grown in triplicate in a range of drug concentrations (0.1 nm-1 mm) for 72 h, following which the cell proliferation was determined by the Alamar Blue assay. Results are expressed as the percent of solvent-treated controls ± s.e. over three separate experiments. dexamethasone, with an ID 50 of Ͼ1 mm compared to 51 nm for the WT cells, representing a greater than 19 000-fold level of resistance (Figure 1b) . In addition, MTX-R3 cells exhibited Ͼ10-fold level of resistance to cytarabine, with ID 50 values of 7.3 ± 1.0 nm and 73.7 ± 21.6 nm for WT and MTX-R3 cells, respectively, over six independent experiments (data not shown). MTX-R3 cells were also highly cross-resistant to the glucocorticoid prednisolone, but were not significantly different from WT cells in their responses to cisplatin, staurosporine, flavopiridol and topotecan (data not shown), indicating that the broad-range drug resistance exhibited by MTX-R3 cells did not extend to all cytotoxic agents. mic protein). The slope of each curve suggested that, at least at 4°C, the receptors from the two cell lines had approximately equal affinity for 3 H-dexamethasone (Figure 2b ).
Glucocorticoid receptor binding studies
Analysis of glucocorticoid receptor expression
Having established reduced glucocorticoid binding in MTX-R3 compared with WT cells, the level of glucocorticoid receptor protein was determined by immunoblot analysis of whole cell extracts (Figure 3a) . Quantification of the band intensities by phosphoimage analysis, in which the glucocorticoid receptor band was normalized to the actin control band, indicated that MTX-R3 cells expressed 63 ± 10% (n = 3) of the immunoreactive glucocorticoid receptor protein compared to WT cells.
Reduced glucocorticoid receptor protein in MTX-R3 cells correlated with a reduction in the expression of full-length (4.8 kb) glucocorticoid receptor mRNA as determined by Northern blot analysis (Figure 3b) . Levels of the glucocorticoid receptor mRNA in MTX-R3 cells, when normalized to the GAPDH loading control, were 55 ± 20% (n = 3) that of WT cells. The results of the Northern blot analysis were supported by semiquantitative RT-PCR, which showed a significant reduction in glucocorticoid receptor mRNA expression in MTX-R3 compared to WT cells relative to ␤ 2 -microglobulin internal controls (data not shown).
DNA sequencing and RFLP analysis of the glucocorticoid receptor gene
The approximate 40% reduction in expression of the glucocorticoid receptor protein in MTX-R3 cells was unable to fully account for the complete lack of ligand binding in the whole cell binding assay (Figure 2a) . Previous work by others has shown that CEM WT cells express mRNA encoding both a GR753F mutant receptor and a wild-type receptor. [6] [7] [8] The entire glucocorticoid receptor cDNA from WT and MTX-R3 cells was sequenced following RT-PCR amplification of overlapping 500 bp fragments. Complete consensus was observed between the published glucocorticoid receptor cDNA sequence, 25 and both the WT and MTX-R3 sequences, with the exception of the third nucleotide of codon 753 (nucleotide 2298). The electropherograms shown in Figure 4a indicated that WT cells were heterozygous for TTA and TTT, while MTX-R3 cells had loss of heterozygosity at codon 753.
The polymorphism arising from the transversion of A to T in the third position of codon 753 results in the removal of an AluI restriction enzyme site (recognition sequence AGCT) and provided an opportunity to confirm the sequencing results by RFLP analysis. Primers were designed to obtain a 444 basepair amplicon encompassing codon 753, which was then digested with AluI. Analysis of digested PCR products confirmed that the WT cells expressed both a GR753F mutant receptor and wild-type receptor, while MTX-R3 cells expressed only the GR753F mutant receptor allele (Figure 4b) .
The glucocorticoid receptor expression analysis and sequencing results provide an explanation for the characteristics of MTX-R3 cells observed in the ligand binding assays, and fully account for the high level of glucocorticoid resistance observed. The GR753F allele encodes an activation-labile receptor that does not bind ligand under physiological conditions, but will bind ligand under stabilizing conditions such as low temperatures (4°C) or in the presence of molybdate ions. 11 The whole cell binding assays were carried out at 37°C Leukemia and showed no ligand binding activity in MTX-R3 cells ( Figure  2a) . However, the cytoplasmic binding assays carried out at 4°C showed an equal affinity but less than half the number of binding sites in MTX-R3 compared to WT cells (Figure 2b ).
The present study has established that selection for methotrexate resistance has resulted in a cell line that is highly resistant to dexamethasone due to silencing of the wild-type glucocorticoid receptor allele originally expressed in WT cells. At present, it remains unclear whether the loss of wild-type glucocorticoid receptor expression in MTX-R3 cells is due to an acquired mutation in the gene or gene deletion. A previous study showed that chemotherapeutic agents cause deletion of the glucocorticoid receptor gene, although the glucocorticoidresistant clones were selected in dexamethasone subsequent to drug treatment. 26 The glucocorticoid resistance in the MTX-R3 population appears to have arisen in the absence of glucocorticoid selection pressure. To our knowledge this is the first report to suggest that exposure to structurally unrelated chemotherapeutic drugs can result in a glucocorticoid-resistant cell line in the absence of additional selection with a glucocorticoid. Our observations raise the possibility that methotrexate may have a causal role in the development of glucocorticoid resistance in childhood ALL.
Alternatively, it is possible that in the process of deriving the methotrexate-resistant MTX-R3 cells, stochastic mutagenic events may have resulted in the selection of a glucocorticoidresistant clone. CEM WT cells have been shown to consist of a mixture of clones with differential glucocorticoid sensitivity, 27 and exhibit a haploid rate of mutation for glucocorticoid resistance. 18 
Nuclear translocation of the glucocorticoid receptor
Smets and colleagues 21 have suggested that a range of stimuli initiate apoptosis of lymphoid cells by ligand-independent nuclear translocation and activation of the glucocorticoid receptor. Glucocorticoid receptor-positive but dexamethasone-resistant variants exhibited cross-resistance to such activation of the receptor by serum starvation or heat shock. In light of this report we undertook experiments to assess nuclear translocation of the glucocorticoid receptor in WT cells exposed to the cytotoxic agents methotrexate and cytarabine. Figure 5a shows that dexamethasone treatment resulted in nuclear translocation of the glucocorticoid receptor, consistent with the study by Smets et al. 21 Moreover, exposure of WT cells to either methotrexate or cytarabine, under conditions that caused negligible loss of cell viability, also resulted in a marked increase in the proportion of nuclear glucocorticoid receptor compared to non-treated controls. Quantitative data are shown in Figure 5b . The immunoblot shown in Figure 5c indicates that nuclear translocation of the glucocorticoid receptor occurred within 4 h of dexamethasone or methotrexate treatment, prior to any decrease in cell viability. Overall, these data indicate that, in the absence of exogenous glucocorticoids, methotrexate and cytarabine induce translocation of the glucocorticoid receptor from the cytoplasm to the nucleus, and that this translocation is an early event occurring prior to cell death. It remains to be determined whether these agents also induce ligand-independent activation of the glucocorticoid receptor.
In summary, our study has provided evidence that the CEM MTX-R3 cell line, selected for high level resistance to methotrexate, is also highly resistant to glucocorticoids due to loss of expression of a functional glucocorticoid receptor allele.
Figure 5
Nuclear translocation of the glucocorticoid receptor in WT cells following exposure to dexamethasone or the cytotoxic agents cytarabine (ara-C) and methotrexate. Cells were exposed to dexamethasone (1 m), cytarabine (100 nm) or methotrexate (1 m) for up to 24 h, harvested and separated into cytoplasmic and nuclear extracts. Equal volumes of nuclear (N) and cytoplasmic (C) extracts were immunoblotted for glucocorticoid receptor. (a) Representative immunoblot showing nuclear translocation of glucocorticoid receptor in response to 24 h exposure to dexamethasone, cytarabine and methotrexate compared to an untreated control. (b) Proportion of glucocorticoid receptor protein in nuclear extracts from cells exposed to dexamethasone, cytarabine or methotrexate for 24 h. Results are the mean ± s.e. of two separate experiments, except for cytarabine which is from a single experiment. (c) Representative immunoblot showing rapid nuclear translocation of glucocorticoid receptor in cells exposed to dexamethasone or methotrexate for 4 h or 8 h. In both (a) and (c), viability was estimated by trypan blue exclusion.
Ligand-independent nuclear translocation of the glucocorticoid receptor induced by methotrexate provides a plausible explanation for the co-selection of high level resistance to methotrexate and glucocorticoids both in the CEM cell line as well as chemotherapy refractory childhood ALL patients. In order to further test this hypothesis, however, more widespread studies are required including those on a wider range of lymphoid cell lines.
